Vigil Neuro
Jade Donaldson currently serves as a Clinical Trial Manager at Vigil Neuroscience, starting in October 2023. Previously, Jade held the position of Principal Clinical Trial Associate at Mersana Therapeutics from January 2022 to October 2023 and has experience as a Clinical Trial Protocol Specialist II and I at ECOG-ACRIN Cancer Research Group between June 2020 and December 2021. Additionally, Jade worked as a Per Diem Clinical Research Associate and as a Clinical Research Associate II and I within the Neuro-Oncology practice group at Massachusetts General Hospital from August 2019 to November 2021. Earlier research experience includes a role as a Psychoendocrinology Research Assistant and Lab Coordinator at Bates College and a Behavioral Neuroscience Research Assistant position at Washington State University. Jade holds a Bachelor of Arts in Neuroscience and Anthropology from Bates College and has completed coursework at the University of Maryland Francis King Carey School of Law.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.